Scintigraphic imaging of HSVtk gene therapy
Related Experiment Video
Updated: Sep 30, 2026
Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis
Published on: August 1, 2019
Erik F J de Vries1, Anne Rixt Buursma, Geke A P Hospers
1PET center, Groningen University Hospital, PO-Box 30.001, 9700 RB Groningen, The Netherlands. e.f.j.de.vries@pet.azg.nl
Abstract:
The evolution of molecular biology has enabled the exploration of novel sophisticated gene-directed treating modalities for cancer. Suicide gene therapy - i.e. transfection of a so-called suicide gene that sensitizes target cells towards a prodrug - may offer an attractive approach to treat malignant tumors. For the development of effective clinical suicide gene therapy protocols, a non-invasive method to assay the extent, the kinetics and the spatial distribution of transgene expression is essential. This would allow investigators and physicians to assess the efficiency of experimental and therapeutic gene transfection protocols and would enable early prognosis of therapy outcome. Radionuclide imaging techniques like single photon emission computed tomography (SPECT) and positron emission tomography (PET), which can non-invasively visualize and quantify metabolic processes in vivo, are being evaluated for repetitive monitoring of transgene expression in living animals and humans. Transgene expression can be monitored directly by imaging the expression of the therapeutic gene itself, or indirectly using a reporter gene that is coupled to the therapeutic gene. Various radiopharmaceuticals have been developed and are now being evaluated for imaging of transgene expression. This review surveys the progress that has been made in the field of non-invasive nuclear imaging of transgene expression and focuses on the herpes simplex virus type 1 thymidine kinase (HSVtk) gene therapy approaches.
Insights
Non-invasive imaging techniques like SPECT and PET are crucial for monitoring cancer suicide gene therapy. These methods track transgene expression, enabling assessment of treatment efficacy and prognosis.
Area of Science:
- Molecular Biology
- Oncology
- Medical Imaging
Background:
- Gene therapy offers novel cancer treatment strategies, including suicide gene therapy.
- Effective suicide gene therapy requires non-invasive methods to monitor transgene expression.
- Current limitations in assessing gene therapy efficacy necessitate advanced monitoring tools.
Purpose of the Study:
- To review advancements in non-invasive nuclear imaging for monitoring transgene expression in gene therapy.
- To highlight the role of SPECT and PET in evaluating suicide gene therapy efficacy.
- To focus on herpes simplex virus type 1 thymidine kinase (HSVtk) gene therapy approaches.
Main Methods:
- Evaluation of radionuclide imaging techniques, including SPECT and PET.
- Assessment of methods for direct and indirect monitoring of transgene expression.
- Review of radiopharmaceuticals developed for imaging transgene expression.
Main Results:
- SPECT and PET enable non-invasive, in vivo visualization and quantification of transgene expression.
- Reporter genes coupled to therapeutic genes facilitate indirect monitoring.
- Development of various radiopharmaceuticals aids in imaging transgene expression.
Conclusions:
- Non-invasive nuclear imaging is essential for assessing suicide gene therapy.
- SPECT and PET provide valuable tools for monitoring gene expression kinetics and distribution.
- HSVtk-based suicide gene therapy benefits from these advanced imaging modalities.
More Related Videos
13:22Detection of the Genome and Transcripts of a Persistent DNA Virus in Neuronal Tissues by Fluorescent In situ Hybridization Combined with Immunostaining
Published on: January 23, 2014
00:06Quantitative Fluorescence In Situ Hybridization (FISH) and Immunofluorescence (IF) of Specific Gene Products in KSHV-Infected Cells
Published on: August 27, 2019